Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACA | Q13085 | 14/20 | 0.58 |
| ▸ | ACACB | O00763 | 5/20 | 0.58 |
| ▸ | TLR4 | O00206 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | FABP1 | P07148 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19405880 | 0.93 | ACACA (0.65) | ACACAACACBPARP15PARP10PARP2 | |
| SCHEMBL19834384 | 0.83 | ACACA (0.55) | ACACAACACBTLR4TLR2RAB9A | |
| SCHEMBL19834471 | 0.82 | ACACA (0.88) | ACACAACACB | |
| SCHEMBL19834467 | 0.81 | ACACA (0.60) | ACACAACACBPARP15PARP10PARP2 | |
| SCHEMBL19405726 | 0.80 | PARP10 (0.71) | ACACAACACBPARP15PARP10PARP2 | |
| SCHEMBL19834363 | 0.80 | ACACA (0.55) | ACACAACACBTLR4TLR2PARP15 | |
| SCHEMBL19834474 | 0.79 | ACACA (0.58) | ACACAACACBTLR4TLR2 | |
| SCHEMBL19405877 | 0.79 | ACACA (0.57) | ACACAACACBPARP15PARP10PARP2 | |
| SCHEMBL2087923 | 0.78 | NR1H4 (0.62) | ACACAACACBPARP15PARP10PARP2 | |
| SCHEMBL19405920 | 0.78 | ACACA (0.57) | ACACAACACBPARP15PARP10PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10252997-B2 | Monocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279183-A1 | MONOCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10252997-B2 | Monocyclic compound | FABP1, CPT1A, GOT2 | ACACA 58/4885ACACB 28/4885TLR4 945/4885 |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | FABP1, CPT1A, GOT2 | ACACA 58/4885ACACB 28/4885TLR4 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.